Drug Safety Archives

Blog

How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most

Learn how Model-Informed Drug Development strengthens drug asset valuation by reducing uncertainty, predicting clinical performance,…

Certara2026 年 1 月 26 日

On-Demand Webinar

Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy

Watch this on-demand webinar to learn how model-based meta-analysis (MBMA), quantitative systems pharmacology (QSP), and…

Certara2026 年 1 月 22 日

Webinar

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

Certara2026 年 1 月 14 日

On-Demand Webinar

安全第一：揭示化合物筛选数据中的临床风险

Learn how to interpret screening assay data to predict clinical off-target risk with ToxStudio® and…

Certara2026 年 1 月 13 日

Fact Sheet

Add Off-target Risk Profiling to Your Analyses

Certara's cheminformatics solution, D360, supports a key feature of Secondary Intelligence: a low-medium-high ranking of…

Certara2026 年 1 月 5 日

Publication

A Systematic Review and Model-Based Meta-Analysis of Pegylated-Interferon-α-Induced HBsAg Loss in Chronic Hepatitis B Virus Infection

This study synthesizes data from a large body of clinical trials to evaluate rates of…

Certara2025 年 12 月 18 日

Case Study

Merck Advances Pediatric Oncology with Innovative ADC Modeling

Merck leveraged ADC modeling and pediatric ADC dose optimization to enable FDA acceptance and advance…

Certara2025 年 12 月 12 日

Case Study

Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling

Discover how Certara applied exposure-response analysis and advanced modeling to optimize Donidalorsen dosing for hereditary…

Certara2025 年 11 月 10 日

On-Demand Webinar

In silico Safety and Toxicology assessment: ToxStudio®

Discover how Certara’s ToxStudio align with FDA’s roadmap to reduce animal testing and transform preclinical…

Certara2025 年 10 月 30 日

On-Demand Webinar

AAPS Webinar – Pediatric Drug Development: Why It’s Critical to Submission Strategy and How Modeling, Regulatory, and Clinical Insights Shape Success

Learn how model-informed drug development, clinical pharmacology, and regulatory strategy support successful pediatric drug development…

Certara2025 年 10 月 21 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

药物安全

How Model-Informed Drug Development (MIDD) Strengthens Drug Asset Valuation and Answers the Questions Investors Care About Most

Model-Based Meta-Analysis (MBMA), Quantitative Systems Pharmacology (QSP), and Advanced Modeling in Early Reimbursement Strategy

CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access

安全第一：揭示化合物筛选数据中的临床风险

Add Off-target Risk Profiling to Your Analyses

A Systematic Review and Model-Based Meta-Analysis of Pegylated-Interferon-α-Induced HBsAg Loss in Chronic Hepatitis B Virus Infection

Merck Advances Pediatric Oncology with Innovative ADC Modeling

Supporting Ionis’ Donidalorsen BLA with Biomarker HAE Attack Rate Modeling

In silico Safety and Toxicology assessment: ToxStudio®

AAPS Webinar – Pediatric Drug Development: Why It’s Critical to Submission Strategy and How Modeling, Regulatory, and Clinical Insights Shape Success

订阅时事通讯

快捷链接

解决方案

联系我们